Volume Alert - PFE 30.32 Pfizer Inc $PFE Hit a hig
Post# of 190
Posted On: 11/20/2014 11:26:32 AM
Volume Alert - PFE 30.32 Pfizer Inc $PFE Hit a high today of 30.47 Closing the day 10:30 at 30.32 -0.12 -0.39% With a day low of 30.25 and a total volume of 3,609,580.
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Early Glance: Pharmaceuticals companies
AP - 56 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.90 (-0.86), BAX: 71.77 (-0.69), PFE: 30.43 (-0.01), BMY: 58.61 (-0.20)
The Crucial Thing You're Missing About Many Dividend Stocks
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 50 mins ago
It's been proved time and time again that investing for the long haul is a better way to build wealth than short-term trading is. It's also been shown that dividend-paying stocks outperform their non-dividend-paying peers. When it comes down to...
ACT: 264.84 (-1.20), PFE: 30.43 (-0.01), AZN: 74.07 (-1.31), BMY: 58.61 (-0.20)
Lilly Shares Climb Despite Sales, Revenue Declines
Stock Traders Daily - at Seeking Alpha - Wed Nov 19, 11:50PM CST
PFE: 30.43 (-0.01), MRK: 59.22 (-0.42), DIA: 176.93 (unch), LLY: 66.86 (-0.35)
Rheumatoid Arthritis Therapeutics Clinical Trials Market by Region, Companies, Trial Status, Phase H2 2014
PRWeb - Wed Nov 19, 7:33PM CST
The clinical trial report, "Rheumatoid Arthritis Global Clinical Trials Review, H2, 2014" provides data on the Rheumatoid Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rheumatoid Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Rheumatoid Arthritis. Complete Report is Available @ http://www.reportsnreports.com/reports/317200...-2014.html .
JNJ: 107.90 (-0.86), PFE: 30.43 (-0.01), MRK: 59.22 (-0.42), AZN: 74.07 (-1.31), ABBV: 65.50 (unch), BMY: 58.61 (-0.20)
Final Glance: Pharmaceuticals companies
AP - Wed Nov 19, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.90 (-0.86), BAX: 71.77 (-0.69), PFE: 30.43 (-0.01), BMY: 58.61 (-0.20)
Is Pfizer Spending Enough On R&D?
Tom Armistead - Seeking Alpha - Wed Nov 19, 3:36PM CST
R&D is a primary growth driver for pharmaceutical companies. Pfizer (NYSE: PFE ) CEO Ian Read, newly appointed at the time, announced draconian cuts to this sensitive expense area on 1/31/2011, and followed through, cutting it from $9.4 billion...
PFE: 30.43 (-0.01), AZN: 74.07 (-1.31)
Midday Glance: Pharmaceuticals companies
AP - Wed Nov 19, 12:31PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 107.90 (-0.86), BAX: 71.78 (-0.68), PFE: 30.43 (-0.01), BMY: 58.61 (-0.20)
Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 9:10AM CST
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 31.45 (+1.92), AGN: 212.02 (-0.57), HD: 97.25 (+0.55), ACT: 264.84 (-1.20), GILD: 103.17 (+0.83), PFE: 30.43 (-0.01), COV: 97.32 (-0.18), ALXN: 192.60 (+0.64)
Pfizer announces availability of first US FDA approved TRUMENBA (Meningococcal Group B Vaccine) in the US
M2 - Wed Nov 19, 6:29AM CST
Science health based company Pfizer (NYSE
FE) reported on Tuesday the launch of the first and only US FDA approved vaccine, TRUMENBA (Meningococcal Group B Vaccine), for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals ten through 25 years of age.
PFE: 30.43 (-0.01)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 264.84 (-1.20), QLTI: 3.92 (-0.07), VRX: 143.04 (+0.57), AGN: 212.02 (-0.57), SHPG: 209.99 (+2.41), AUXL: 33.10 (+0.07), ABBV: 65.50 (unch), SNY: 46.98 (-1.11), ABT: 43.45 (+0.02), ENDP: 69.23 (+0.22), AKRX: 38.06 (-0.12), PFE: 30.43 (-0.01), INCY: 71.95 (+0.65), SLXP: 102.49 (-1.14), MYL: 55.66 (-0.02), AMGN: 164.16 (+1.52), LLY: 66.87 (-0.34), GSK: 46.39 (+0.14), BMY: 58.61 (-0.20), ACHN: 13.24 (+0.33), MRK: 59.22 (-0.42), AZN: 74.07 (-1.31), ICPT: 156.50 (+0.57), TEVA: 57.27 (+0.02), NVS: 95.58 (-0.15)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 264.84 (-1.20), QLTI: 3.92 (-0.07), VRX: 143.04 (+0.57), AGN: 212.02 (-0.57), SHPG: 209.99 (+2.41), AUXL: 33.10 (+0.07), ABBV: 65.50 (unch), SNY: 46.98 (-1.11), ABT: 43.45 (+0.02), ENDP: 69.23 (+0.22), AKRX: 38.06 (-0.12), PFE: 30.43 (-0.01), INCY: 71.95 (+0.65), SLXP: 102.49 (-1.14), MYL: 55.66 (-0.02), AMGN: 164.16 (+1.52), LLY: 66.87 (-0.34), GSK: 46.39 (+0.14), BMY: 58.61 (-0.20), ACHN: 13.24 (+0.33), MRK: 59.22 (-0.42), AZN: 74.07 (-1.31), ICPT: 156.50 (+0.57), TEVA: 57.27 (+0.02), NVS: 95.58 (-0.15)
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:15PM CST
Merck KGaA (MKGAF) inked a deal with Pfizer to co-develop and co-commercialize MSB0010718C as a potential treatment for multiple types of tumor.
LCI: 46.82 (-0.02), PFE: 30.43 (-0.01), BIOD: 1.59 (+0.04)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KO: 44.30 (+0.08), KMI: 41.21 (+0.27), GE: 26.93 (+0.01), F: 15.48 (+0.04), ABX.TO: 14.29 (+0.20), K.TO: 3.15 (+0.05), ABX: 12.65 (+0.19), KGC: 2.79 (+0.05), PFE: 30.43 (-0.01), HAL: 49.04 (+0.61), BAC: 16.99 (-0.07), EMC: 29.99 (+0.06), DNR: 9.82 (+0.13), TWTR: 40.07 (+0.36), BHI: 64.23 (+0.72)
Zoetis 2015 Guidance Misses As Buyout Theories Abound
at Investor's Business Daily - Tue Nov 18, 2:15PM CST
Animal-health giant Zoetis (ZTS) offered 2015 guidance below the Street's consensus along with longer-term financial goals at its analyst day Tuesday. After a brief halt in trading for the early-afternoon announcement, the stock was down more than 1%...
AGN: 212.02 (-0.57), ZTS: 42.99 (-0.41), ABT: 43.45 (+0.02), ACT: 264.84 (-1.20), VRX: 143.04 (+0.57), PFE: 30.43 (-0.01)
Cramer: Zoetis Defends Against Takeover; GoPro Is Going Higher
at The Street - Tue Nov 18, 9:55AM CST
TheStreet's Jim Cramer says Zoetis' $500 million buyback is a defense tactic to prevent a takeover, while shares of GoPro are headed higher despite its secondary offering.
ZTS: 42.99 (-0.41), GPRO: 74.24 (-4.85), VRX: 143.04 (+0.57), PFE: 30.43 (-0.01)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.45 (+0.02), PFE: 30.43 (-0.01), AZN: 74.07 (-1.31), LLY: 66.86 (-0.35), GSK: 46.39 (+0.14), NVS: 95.58 (-0.15)
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Early Glance: Pharmaceuticals companies
AP - 56 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.90 (-0.86), BAX: 71.77 (-0.69), PFE: 30.43 (-0.01), BMY: 58.61 (-0.20)
The Crucial Thing You're Missing About Many Dividend Stocks
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 50 mins ago
It's been proved time and time again that investing for the long haul is a better way to build wealth than short-term trading is. It's also been shown that dividend-paying stocks outperform their non-dividend-paying peers. When it comes down to...
ACT: 264.84 (-1.20), PFE: 30.43 (-0.01), AZN: 74.07 (-1.31), BMY: 58.61 (-0.20)
Lilly Shares Climb Despite Sales, Revenue Declines
Stock Traders Daily - at Seeking Alpha - Wed Nov 19, 11:50PM CST
PFE: 30.43 (-0.01), MRK: 59.22 (-0.42), DIA: 176.93 (unch), LLY: 66.86 (-0.35)
Rheumatoid Arthritis Therapeutics Clinical Trials Market by Region, Companies, Trial Status, Phase H2 2014
PRWeb - Wed Nov 19, 7:33PM CST
The clinical trial report, "Rheumatoid Arthritis Global Clinical Trials Review, H2, 2014" provides data on the Rheumatoid Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rheumatoid Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Rheumatoid Arthritis. Complete Report is Available @ http://www.reportsnreports.com/reports/317200...-2014.html .
JNJ: 107.90 (-0.86), PFE: 30.43 (-0.01), MRK: 59.22 (-0.42), AZN: 74.07 (-1.31), ABBV: 65.50 (unch), BMY: 58.61 (-0.20)
Final Glance: Pharmaceuticals companies
AP - Wed Nov 19, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.90 (-0.86), BAX: 71.77 (-0.69), PFE: 30.43 (-0.01), BMY: 58.61 (-0.20)
Is Pfizer Spending Enough On R&D?
Tom Armistead - Seeking Alpha - Wed Nov 19, 3:36PM CST
R&D is a primary growth driver for pharmaceutical companies. Pfizer (NYSE: PFE ) CEO Ian Read, newly appointed at the time, announced draconian cuts to this sensitive expense area on 1/31/2011, and followed through, cutting it from $9.4 billion...
PFE: 30.43 (-0.01), AZN: 74.07 (-1.31)
Midday Glance: Pharmaceuticals companies
AP - Wed Nov 19, 12:31PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 107.90 (-0.86), BAX: 71.78 (-0.68), PFE: 30.43 (-0.01), BMY: 58.61 (-0.20)
Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 9:10AM CST
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 31.45 (+1.92), AGN: 212.02 (-0.57), HD: 97.25 (+0.55), ACT: 264.84 (-1.20), GILD: 103.17 (+0.83), PFE: 30.43 (-0.01), COV: 97.32 (-0.18), ALXN: 192.60 (+0.64)
Pfizer announces availability of first US FDA approved TRUMENBA (Meningococcal Group B Vaccine) in the US
M2 - Wed Nov 19, 6:29AM CST
Science health based company Pfizer (NYSE
FE) reported on Tuesday the launch of the first and only US FDA approved vaccine, TRUMENBA (Meningococcal Group B Vaccine), for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals ten through 25 years of age. PFE: 30.43 (-0.01)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 264.84 (-1.20), QLTI: 3.92 (-0.07), VRX: 143.04 (+0.57), AGN: 212.02 (-0.57), SHPG: 209.99 (+2.41), AUXL: 33.10 (+0.07), ABBV: 65.50 (unch), SNY: 46.98 (-1.11), ABT: 43.45 (+0.02), ENDP: 69.23 (+0.22), AKRX: 38.06 (-0.12), PFE: 30.43 (-0.01), INCY: 71.95 (+0.65), SLXP: 102.49 (-1.14), MYL: 55.66 (-0.02), AMGN: 164.16 (+1.52), LLY: 66.87 (-0.34), GSK: 46.39 (+0.14), BMY: 58.61 (-0.20), ACHN: 13.24 (+0.33), MRK: 59.22 (-0.42), AZN: 74.07 (-1.31), ICPT: 156.50 (+0.57), TEVA: 57.27 (+0.02), NVS: 95.58 (-0.15)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 264.84 (-1.20), QLTI: 3.92 (-0.07), VRX: 143.04 (+0.57), AGN: 212.02 (-0.57), SHPG: 209.99 (+2.41), AUXL: 33.10 (+0.07), ABBV: 65.50 (unch), SNY: 46.98 (-1.11), ABT: 43.45 (+0.02), ENDP: 69.23 (+0.22), AKRX: 38.06 (-0.12), PFE: 30.43 (-0.01), INCY: 71.95 (+0.65), SLXP: 102.49 (-1.14), MYL: 55.66 (-0.02), AMGN: 164.16 (+1.52), LLY: 66.87 (-0.34), GSK: 46.39 (+0.14), BMY: 58.61 (-0.20), ACHN: 13.24 (+0.33), MRK: 59.22 (-0.42), AZN: 74.07 (-1.31), ICPT: 156.50 (+0.57), TEVA: 57.27 (+0.02), NVS: 95.58 (-0.15)
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:15PM CST
Merck KGaA (MKGAF) inked a deal with Pfizer to co-develop and co-commercialize MSB0010718C as a potential treatment for multiple types of tumor.
LCI: 46.82 (-0.02), PFE: 30.43 (-0.01), BIOD: 1.59 (+0.04)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KO: 44.30 (+0.08), KMI: 41.21 (+0.27), GE: 26.93 (+0.01), F: 15.48 (+0.04), ABX.TO: 14.29 (+0.20), K.TO: 3.15 (+0.05), ABX: 12.65 (+0.19), KGC: 2.79 (+0.05), PFE: 30.43 (-0.01), HAL: 49.04 (+0.61), BAC: 16.99 (-0.07), EMC: 29.99 (+0.06), DNR: 9.82 (+0.13), TWTR: 40.07 (+0.36), BHI: 64.23 (+0.72)
Zoetis 2015 Guidance Misses As Buyout Theories Abound
at Investor's Business Daily - Tue Nov 18, 2:15PM CST
Animal-health giant Zoetis (ZTS) offered 2015 guidance below the Street's consensus along with longer-term financial goals at its analyst day Tuesday. After a brief halt in trading for the early-afternoon announcement, the stock was down more than 1%...
AGN: 212.02 (-0.57), ZTS: 42.99 (-0.41), ABT: 43.45 (+0.02), ACT: 264.84 (-1.20), VRX: 143.04 (+0.57), PFE: 30.43 (-0.01)
Cramer: Zoetis Defends Against Takeover; GoPro Is Going Higher
at The Street - Tue Nov 18, 9:55AM CST
TheStreet's Jim Cramer says Zoetis' $500 million buyback is a defense tactic to prevent a takeover, while shares of GoPro are headed higher despite its secondary offering.
ZTS: 42.99 (-0.41), GPRO: 74.24 (-4.85), VRX: 143.04 (+0.57), PFE: 30.43 (-0.01)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.45 (+0.02), PFE: 30.43 (-0.01), AZN: 74.07 (-1.31), LLY: 66.86 (-0.35), GSK: 46.39 (+0.14), NVS: 95.58 (-0.15)
(0)
(0)Pfizer Inc. (PFE) Stock Research Links
Scroll down for more posts ▼